{"id":"W4391544195","doi":"10.1016/s2213-8587(23)00356-x","title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Placebo; Agonist; Glucagon-like peptide 1 receptor; Liraglutide; Glucagon-like peptide-1; Double blind; Internal medicine; Diabetes mellitus; Pharmacology; Endocrinology; Type 2 diabetes; Receptor; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001219301,0.000433966,0.001547358,0.0002624812,0.0003241434,0.0002730337,0.0002102407,0.0001205838,0.0001622063],"category_scores_gemma":[0.0001980684,0.0002845785,0.0003714342,0.0002158038,0.0003136598,0.0001272008,0.0001600922,0.0003392663,0.0001004574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001160289,"about_ca_system_score_gemma":0.0001090281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002316203,"about_ca_topic_score_gemma":0.00002300655,"domain_scores_codex":[0.9968111,0.0001902016,0.0005489176,0.0006582544,0.0002273161,0.001564199],"domain_scores_gemma":[0.9975756,0.001537386,0.000139351,0.0005348257,0.00005621371,0.0001566531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9271325,0.0006501554,0.0007775896,0.0005066887,0.004059788,0.0001020804,0.0003406114,0.000002457263,0.004311496,0.01028585,0.01492063,0.03691016],"study_design_scores_gemma":[0.850269,0.002111423,0.00005818572,0.0001218864,0.002197295,0.00001371692,0.00008618503,0.0003865813,0.005036033,0.0006424355,0.1388021,0.000275187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9706236,0.006258501,0.00004205373,0.008982417,0.002030673,0.008533866,0.00007852584,0.0003816987,0.003068668],"genre_scores_gemma":[0.9848518,0.0009769081,0.0003426626,0.0009913733,0.002987877,0.004461993,0.0003229242,0.00008168218,0.004982811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1238814,"threshold_uncertainty_score":0.9999607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05994524410212917,"score_gpt":0.343542484035551,"score_spread":0.2835972399334218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}